Calcium Levofolinate: A Comprehensive Pharmacological and Clinical Monograph

Executive Summary

Calcium levofolinate is a critical adjuvant medication in modern oncology and hematology, representing the pharmacologically active levo-isomer of folinic acid. Unlike its racemic counterpart, leucovorin, which contains an equal mixture of the active levo-isomer and an inactive dextro-isomer, calcium levofolinate delivers a purified, potent form of the drug. This monograph provides a comprehensive analysis of its chemical properties, dual mechanisms of action, pharmacokinetics, clinical applications, and safety profile.

Pharmacodynamically, calcium levofolinate serves two distinct and vital roles. First, as a cytoprotective agent, it provides a reduced folate source that bypasses the enzymatic block induced by folic acid antagonists like high-dose methotrexate. This "rescue" mechanism selectively protects healthy cells from toxicity, enabling the use of more aggressive and effective chemotherapy regimens. Second, it acts as a synergistic potentiator of fluoropyrimidine-based chemotherapy, most notably 5-fluorouracil (5-FU). By forming a stable ternary complex with the enzyme thymidylate synthase and the active metabolite of 5-FU, it prolongs the inhibition of DNA synthesis in cancer cells, thereby enhancing the drug's cytotoxic efficacy. This dual functionality has established it as a cornerstone of treatment for osteosarcoma and as a gold standard in combination regimens for metastatic colorectal cancer.

The pharmacokinetic profile of calcium levofolinate is characterized by rapid conversion to its primary active metabolite, 5-methyltetrahydrofolate (5-MTHF). While parenteral administration ensures complete bioavailability, oral absorption is saturable, limiting the effectiveness of high oral doses. The drug distributes widely throughout the body, including the central nervous system, and is primarily eliminated via renal excretion.

Clinically, its approved indications include high-dose methotrexate rescue, management of folic acid antagonist overdose, palliative treatment of advanced colorectal cancer in combination with 5-FU, and treatment of folate-deficient megaloblastic anemia. An emerging indication for the treatment of cerebral folate deficiency is also under regulatory consideration. Despite its broad utility, its use requires meticulous attention to administration protocols. The timing of its administration is critical: it must be given after methotrexate to prevent therapeutic nullification but with 5-FU to ensure synergistic activity.

The safety profile of calcium levofolinate as a monotherapy is excellent, with adverse effects being rare. However, when used in combination with 5-FU, it significantly amplifies the latter's toxicity, particularly gastrointestinal side effects such as severe diarrhea and stomatitis, which can be dose-limiting and potentially fatal, especially in elderly patients. Key contraindications include known hypersensitivity and the treatment of pernicious anemia, where it can mask hematological signs while allowing irreversible neurological damage to progress. Clinically significant drug interactions occur with fluoropyrimidines, folic acid antagonists, and certain anticonvulsant medications. This report synthesizes current evidence to provide a definitive resource for clinicians and researchers on the optimal and safe use of calcium levofolinate.

Molecular Profile and Stereochemistry

Nomenclature, Synonyms, and Key Identifiers

Calcium levofolinate is a folate analog and the calcium salt of levofolinic acid.[1] Its precise chemical identity is crucial for understanding its pharmacology, yet it is known by a wide array of synonyms that can cause confusion in clinical and research settings. The International Union of Pure and Applied Chemistry (IUPAC) name is calcium (2S)-2-{methyl}amino)phenyl]formamido}pentanedioate.[2]

Common synonyms include Levoleucovorin Calcium, (6S)-calcium folinate, L-Leucovorin calcium, Folinic acid L-form calcium salt, Isovorin, and Elvorine.[2] Historically, it has also been referred to as the Citrovorum factor, a term derived from early microbiological assays.[5] In clinical literature, the terms "folinic acid" and "leucovorin" are often used interchangeably with "calcium folinate".[6] However, these terms can ambiguously refer to either the pure levo-isomer (levofolinate) or the racemic mixture (leucovorin), necessitating careful disambiguation based on context.

For unambiguous identification in databases and regulatory filings, the following identifiers are used:

• CAS Number: 80433-71-2 [2]
• UNII (Unique Ingredient Identifier): 778XL6VBS8 [2]
• DrugBank ID: DB11596 (Levoleucovorin) [10]

Chemical Structure and Physicochemical Properties

Calcium levofolinate is a complex organic molecule consisting of a pteridine ring system, a p-aminobenzoyl moiety, and an L-glutamic acid residue, chelated with a calcium ion. Its molecular formula is , with an average molecular weight of 511.508 g/mol.[2] Pharmaceutical preparations are often in the pentahydrate form, , which has a molecular weight of 601.6 g/mol.[13]

Physically, it appears as a white to light yellow, amorphous or crystalline hygroscopic powder.[9] Its solubility in water is limited, with predictive models suggesting a value of 0.514 mg/mL, although this can be enhanced with ultrasonic energy and warming.[2] The limited solubility of the calcium salt is a critical factor in its formulation and administration; for instance, it should not be mixed in the same infusion as 5-fluorouracil, as a precipitate may form.[15] This has led to the development of alternative formulations, such as a more soluble sodium salt, to improve clinical convenience.[16] For long-term stability, the powdered form should be stored desiccated at -20°C.[9]

Property	Value	Source(s)
IUPAC Name	calcium (2S)-2-{methyl}amino)phenyl]formamido}pentanedioate	2
Molecular Formula		2
Average Molecular Weight	511.508 g/mol	2
CAS Number	80433-71-2	2
Appearance	White to light yellow powder	9
Water Solubility	0.514 mg/mL (predicted); 26.5 mg/mL (with ultrasonic/warming)	2
pKa (Strongest Acidic)	3.47 (predicted)	2
pKa (Strongest Basic)	2.81 (predicted)	2
Storage (Powder)	Desiccate at -20°C	9

The Folate Pathway: Relationship to Folic Acid and Tetrahydrofolate

Calcium levofolinate is a direct derivative of the B-vitamin folate metabolic pathway. It is a 5-formyl derivative of tetrahydrofolic acid (THF), which is the central active coenzyme form of folate in the body.[6] The essential function of THF and its derivatives is to act as carriers of one-carbon units in a variety of biosynthetic reactions, including the synthesis of purines (adenine, guanine) and the pyrimidine nucleotide thymidylate, which are essential building blocks for DNA and RNA.[2]

The critical distinction between calcium levofolinate and its dietary precursor, folic acid, lies in their state of reduction. Folic acid is a fully oxidized, synthetic form of the vitamin that is metabolically inert. To become active, it must undergo a two-step reduction process catalyzed by the enzyme dihydrofolate reductase (DHFR), first to dihydrofolate (DHF) and then to THF.[10] Calcium levofolinate, being an already reduced form of folate, bypasses this DHFR-dependent activation step entirely.[5] Once administered, it is readily converted within the body into other biologically active reduced folates, such as 5,10-methylenetetrahydrofolate and the primary circulating form, 5-methyltetrahydrofolate (5-MTHF).[7] This biochemical property is the foundation of its principal mechanisms of action in medicine.

Stereoisomeric Significance: Differentiating Levofolinate from Racemic Leucovorin

A point of paramount importance in the pharmacology of folinic acid is its stereochemistry. The commonly available medication known as leucovorin or calcium folinate is a 1:1 racemic mixture of two diastereoisomers: the dextrorotary (d- or (6R)-) isomer and the levorotary (l- or (6S)-) isomer.[2] Extensive research has established that only the levo-isomer possesses biological activity.[1] Calcium levofolinate is a purified formulation containing exclusively this pharmacologically active (6S)-isomer.

The dextro-isomer is not only inactive but also follows a distinct metabolic and pharmacokinetic path. While the active l-isomer is rapidly metabolized to 5-MTHF, the d-isomer is not metabolized and is cleared from the body much more slowly, primarily through renal excretion.[2] Nonclinical studies have demonstrated that the half-life of the active levoleucovorin is significantly shorter than that of the inactive d-leucovorin, reflecting its rapid metabolic conversion compared to the slow renal clearance of the d-isomer.[21]

This stereochemical distinction has profound clinical implications. When a patient is administered racemic leucovorin, 50% of the dose consists of an inert substance that provides no therapeutic benefit but still contributes to the body's metabolic and excretory load. This "inactive isomer burden" is particularly relevant for patients with compromised renal function. In such individuals, the clearance of the slowly excreted d-isomer could be further impaired, potentially increasing the overall solute load or creating unforeseen competition for renal transporters. The use of pure calcium levofolinate eliminates this burden by delivering only the active moiety. This makes it a more refined therapeutic agent, offering a more predictable dose-response relationship and potentially a more favorable safety profile in renally impaired patients by halving the amount of substance requiring renal clearance. Therefore, the choice between levofolinate and racemic leucovorin is not merely a matter of potency but also one of pharmacological precision and patient safety.

Pharmacodynamics: Dual Mechanisms of Cellular Action

The clinical utility of calcium levofolinate stems from two distinct, context-dependent mechanisms of action at the cellular level. It can function as a cytoprotective antidote to folic acid antagonists or as a synergistic enhancer of fluoropyrimidine chemotherapy. This duality is central to its role in oncology.

The Methotrexate Rescue Mechanism: Bypassing Dihydrofolate Reductase Inhibition

The primary application of calcium levofolinate as a cytoprotective agent is in high-dose methotrexate (MTX) therapy. MTX is a potent chemotherapeutic agent that functions as a folic acid antagonist. It competitively inhibits the enzyme dihydrofolate reductase (DHFR), thereby blocking the conversion of DHF to the active THF.[2] This enzymatic blockade halts the de novo synthesis of purines and thymidylate, which are essential for DNA and RNA replication. The resulting depletion of nucleotides is particularly cytotoxic to rapidly dividing cells, including both cancer cells and healthy host cells such as those in the bone marrow and gastrointestinal mucosa.[20]

Calcium levofolinate's mechanism of "rescue" is elegantly simple: it bypasses the MTX-induced blockade. As a pre-reduced folate analog (a 5-formyl derivative of THF), it does not require DHFR for its activation.[5] It is transported into cells and readily converted to THF and other active folate cofactors, effectively replenishing the depleted intracellular pool.[2] This allows healthy, non-cancerous cells to resume normal DNA and RNA synthesis, thereby mitigating the severe, dose-limiting toxicities of MTX, such as myelosuppression and mucositis.[18] This selective protection of normal tissues, known as "folinic acid rescue" or "leucovorin rescue," is a cornerstone of high-dose MTX protocols, enabling the administration of tumoricidal drug concentrations that would otherwise be lethal to the patient.[8]

Potentiation of Fluoropyrimidines: Covalent Stabilization of the Thymidylate Synthase Complex

In stark contrast to its role as a rescue agent, calcium levofolinate acts as a potent synergistic enhancer when co-administered with fluoropyrimidine chemotherapies like 5-fluorouracil (5-FU). The primary cytotoxic mechanism of 5-FU involves its intracellular conversion to the active metabolite 5-fluorodeoxyuridine monophosphate (FdUMP). FdUMP then binds to and inhibits the enzyme thymidylate synthase (TS), which is responsible for the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), a crucial step in DNA synthesis.[7]

The binding of FdUMP to TS is reversible and relatively weak when it occurs alone. Calcium levofolinate dramatically enhances this inhibition. It is converted intracellularly to the reduced folate cofactor 5,10-methylenetetrahydrofolate, which acts as a molecular "glue." This cofactor joins with FdUMP and TS to form a highly stable, covalent ternary complex.[5] The formation of this stable complex effectively locks the enzyme in an inactive state, leading to a prolonged and more profound inhibition of TS.[7] This enhanced enzymatic inhibition results in a severe depletion of thymidylate, leading to "thymineless death" in cancer cells and a significant potentiation of 5-FU's antitumor activity. This synergistic interaction is the biochemical foundation for combination chemotherapy regimens such as FOLFOX (FOLinic acid, Fluorouracil, OXaliplatin) and FOLFIRI (FOLinic acid, Fluorouracil, IRInotecan), which are standard-of-care treatments for metastatic colorectal cancer.[4]

Cellular Transport and Intracellular Polyglutamylation

The efficacy of calcium levofolinate is further dependent on its transport into cells and its subsequent intracellular processing. It crosses cell membranes through a combination of active and passive transport mechanisms.[10] Once inside the cell, both levofolinate and its principal active metabolite, 5-MTHF, undergo polyglutamylation. This process, catalyzed by the enzyme folylpolyglutamate synthetase, involves the addition of multiple glutamate residues to the molecule.[10] Polyglutamylation serves two key functions: it traps the active folate cofactors within the cell, preventing their efflux, and it increases their affinity for folate-dependent enzymes.[6] This results in a higher intracellular concentration and prolonged retention of the active cofactors, maximizing their ability to participate in the biochemical pathways of both methotrexate rescue and 5-FU potentiation.

The dual and opposing pharmacodynamic roles of calcium levofolinate necessitate a critical understanding of its clinical application. It functions as an antagonist to methotrexate but a synergist to 5-FU. This fundamental dichotomy directly governs the timing of its administration, a factor that is paramount to achieving the desired therapeutic outcome. For methotrexate rescue, levofolinate must be administered on a delayed schedule, typically 24 hours after the methotrexate infusion, to allow the antifolate to exert its cytotoxic effect on cancer cells before the rescue process begins.[1] Administering it concurrently with methotrexate would neutralize the chemotherapy, leading to therapeutic failure. Conversely, for 5-FU potentiation, levofolinate must be administered either immediately prior to or concurrently with the 5-FU dose to ensure that the necessary folate cofactor is available at the time of FdUMP binding to thymidylate synthase.[7] This strict, mechanism-driven scheduling highlights a significant potential for medication error in clinical practice. An error in timing—for instance, applying a 5-FU protocol to a methotrexate regimen—could result in either profound toxicity or a complete lack of efficacy, underscoring the need for rigorous protocol adherence and verification in oncology pharmacy and nursing.

Comprehensive Pharmacokinetic Profile (ADME)

The pharmacokinetic profile of calcium levofolinate describes its journey through the body, which is characterized by route-dependent absorption, extensive distribution, rapid metabolism into active forms, and efficient renal excretion.

Absorption: Route-Dependent Bioavailability and Saturable Transport

The absorption of calcium levofolinate is highly dependent on the route of administration.

• Oral Administration: Following oral administration, the drug is rapidly absorbed from the gastrointestinal tract. However, the absorption process is mediated by a saturable transport mechanism, leading to dose-dependent bioavailability.[5] At lower doses, absorption is highly efficient, with an apparent bioavailability of 97% for a 25 mg dose. As the dose increases, the transport mechanism becomes saturated, and bioavailability decreases significantly to 75% for a 50 mg dose and only 37% for a 100 mg dose.[5] Consequently, oral administration of doses exceeding 25–50 mg is not recommended, as it provides unreliable and incomplete absorption. For higher doses required in many oncologic protocols, parenteral administration is mandatory.[7]
• Parenteral Administration: Intravenous (IV) injection or infusion bypasses the absorption phase entirely, providing immediate and 100% bioavailability. This is the preferred route for high-dose methotrexate rescue and for combination therapy with 5-FU to ensure predictable and complete drug delivery.[25] After a rapid IV dose, peak plasma concentrations of total reduced folates are achieved almost instantaneously.[10]

Distribution: Tissue Penetration, Volume of Distribution, and CNS Access

Once in systemic circulation, calcium levofolinate and its metabolites are widely distributed throughout the body. The drug penetrates all tissues, including the liver, where it concentrates, and readily crosses the blood-brain barrier to enter the cerebrospinal fluid (CSF).[7] The volume of distribution (Vd) has been reported to be approximately 3.2 L/kg, indicating extensive tissue distribution.[7] Plasma protein binding is moderate, with reported values varying between approximately 15% and 35–45%.[5]

Metabolism: Conversion to 5-Methyltetrahydrofolate and Other Active Derivatives

Calcium levofolinate is a prodrug that undergoes rapid and extensive metabolism to form its active derivatives. The primary metabolic conversion is to 5-methyltetrahydrofolate (5-MTHF), which is the principal and most abundant active form of folate circulating in the plasma.[10] This conversion occurs in the intestinal mucosa during oral absorption and in the liver.[5] As previously noted, this metabolic activation is a key feature of the active l-isomer. The d-isomer present in racemic leucovorin is not metabolized and is instead slowly excreted unchanged.[2]

Excretion: Renal Clearance and Elimination Half-Life

The elimination of calcium levofolinate and its metabolites occurs primarily through the kidneys. Approximately 80–90% of an administered dose is excreted in the urine, with a smaller fraction (5–8%) eliminated in the feces.[7]

The elimination half-life varies depending on the specific compound being measured. The parent drug, levofolinic acid, is cleared very rapidly from the plasma, with a reported half-life of approximately 32–45 minutes.[7] In contrast, the active metabolite, 5-MTHF, has a much longer terminal half-life, reported to be in the range of 2.3 to 6.8 hours.[7] This longer half-life of the active moiety is responsible for the sustained biological effect of the drug after the parent compound has been cleared.

Parameter	Value	Notes	Source(s)
Oral Bioavailability	Dose-dependent (saturable)	97% at 25 mg; 75% at 50 mg; 37% at 100 mg	5
Distribution	All tissues, including CNS	Concentrates in liver and CSF	7
Volume of Distribution (Vd)	3.2 L/kg	Indicates extensive tissue distribution	7
Plasma Protein Binding	15% to 45%	Reports vary	5
Primary Metabolism	Conversion to 5-methyltetrahydrofolate (5-MTHF)	Occurs in intestinal mucosa and liver	5
Route of Elimination	Primarily renal	80-90% in urine, 5-8% in feces	7
Half-life (Parent Drug)	~32-45 minutes	Very rapid clearance	7
Half-life (Active 5-MTHF)	~2.3-6.8 hours	Sustained biological activity	7

Clinical Applications and Therapeutic Indications

Calcium levofolinate has a well-established and diverse range of clinical applications, primarily centered on oncology and hematology. Its indications span from serving as an essential component of curative-intent chemotherapy to acting as a vital antidote in cases of drug toxicity.

Adjuvant in Oncology: Enhancing 5-Fluorouracil Efficacy in Metastatic Colorectal Cancer

One of the most significant roles of calcium levofolinate is as a biomodulator of 5-fluorouracil (5-FU). It is approved for use in combination with 5-FU for the palliative treatment of patients with advanced metastatic colorectal cancer.[2] The combination of a folinate salt with 5-FU is considered a global "gold standard" in the systemic therapy of gastrointestinal malignancies, including colorectal and gastric cancers, and has been shown to prolong patient survival.[5] In this context, calcium levofolinate is not merely a supportive agent but an integral part of the therapeutic mechanism, directly enhancing the cytotoxicity of 5-FU. This has fundamentally altered its clinical perception, elevating it from a simple "rescue" drug to an indispensable component of many standard chemotherapeutic regimens.

Cytoprotective Agent: High-Dose Methotrexate Rescue Protocols

Calcium levofolinate is a critical cytoprotective agent used in conjunction with high-dose methotrexate (HDMTX) therapy. It is specifically approved as a rescue agent following HDMTX in the treatment of osteosarcoma.[1] The administration of levofolinate allows clinicians to use much higher, more effective doses of methotrexate than would be tolerable otherwise. It selectively rescues healthy host cells from the antifolate's toxic effects, primarily myelosuppression and severe mucositis, without compromising the antitumor activity of methotrexate.[6] This application is a classic example of its role in supportive oncologic care.

Antidotal Therapy: Management of Folic Acid Antagonist Overdose and Impaired Elimination

Building on its rescue mechanism, calcium levofolinate is indicated as an antidote for toxicities arising from either an inadvertent overdose of a folic acid antagonist or from impaired elimination of such drugs. This includes overdosages of methotrexate, as well as other antifolates like pyrimethamine (an antiprotozoal) and trimethoprim (an antibiotic component).[5] It is also employed in cases of methanol poisoning, where it helps facilitate the metabolism of formic acid, the toxic metabolite of methanol.[6] In these situations, prompt administration is crucial, as its effectiveness diminishes with time.

Treatment of Folate-Deficient Megaloblastic Anemia

Outside of oncology, calcium levofolinate is approved for the treatment of megaloblastic anemia resulting from folic acid deficiency.[4] It is typically reserved for patients in whom oral folic acid therapy is not feasible, such as those with severe malabsorption syndromes.[5] By providing a pre-reduced, active form of folate, it directly replenishes the cofactors needed for normal erythropoiesis.

Emerging Indication: Management of Cerebral Folate Deficiency

A novel and significant application for folinate therapy is emerging in the field of neurology. The U.S. Food and Drug Administration (FDA) has begun the approval process to repurpose leucovorin calcium for the treatment of cerebral folate deficiency (CFD).[6] CFD is a rare neurological syndrome characterized by impaired folate transport across the blood-brain barrier, leading to low folate levels in the central nervous system despite normal systemic levels. This can result in severe developmental delays, seizures, and movement disorders. By providing a form of folate that can more readily enter the CNS, leucovorin has shown promise in improving symptoms in this patient population. This potential new indication marks a significant expansion of the drug's therapeutic identity beyond its traditional roles in oncology and hematology.

Administration, Dosing, and Formulation

The safe and effective use of calcium levofolinate requires strict adherence to established protocols for administration, dosing, and formulation handling, which vary significantly by clinical indication.

Available Formulations and Routes of Administration

Calcium levofolinate is available in several formulations to accommodate different clinical needs:

• Oral Tablets: Typically available in strengths of 5 mg, 10 mg, 15 mg, and 25 mg.[31] This route is suitable for low-dose requirements, such as in the treatment of megaloblastic anemia, but is limited by saturable absorption.[25]
• Parenteral Formulations: Available as a solution for injection or as a lyophilized powder for reconstitution.[14] Parenteral routes include intravenous (IV) and intramuscular (IM) injection.[6] The IV route is standard for most oncologic applications to ensure complete and predictable bioavailability.

A critical and absolute warning pertains to its administration: Calcium levofolinate must never be administered intrathecally. Inadvertent intrathecal administration can lead to severe adverse events, including death.[7] This is because high concentrations of folates in the CNS can be neurotoxic and can counteract the effects of intrathecally administered methotrexate.

Indication-Specific Dosing Regimens and Clinical Protocols

Dosing of calcium levofolinate is highly specific to the indication and often requires patient-specific adjustments based on laboratory monitoring.

Indication	Typical Regimen	Key Considerations	Source(s)
High-Dose Methotrexate Rescue	Initial: 7.5 mg (approx. 5 mg/m²) IV every 6 hours, starting 24 hours after MTX infusion begins.	Dose is titrated based on serum methotrexate and creatinine levels. Can be escalated to 150 mg IV every 3 hours for delayed MTX elimination.	1
Combination with 5-FU (Colorectal Cancer)	Bimonthly (e.g., FOLFOX): 100 mg/m² levofolinic acid IV infusion over 2 hours, followed by 5-FU bolus and infusion.	Regimens vary (weekly, monthly). Levofolinate is given just before or with 5-FU. Dose is not adjusted for toxicity; 5-FU dose is reduced instead.	26
Folic Acid Antagonist Overdose	Initial: 7.5 mg IV every 6 hours.	Dose should be equal to or greater than the antagonist dose. Administer as soon as possible. Can be increased to 50 mg/m² IV every 3 hours based on MTX/creatinine levels.	24
Megaloblastic Anemia	Up to 1 mg daily (parenterally).	Used when oral therapy is not feasible. Doses >1 mg/day show no greater efficacy.	14

Critical Administration Parameters: Infusion Rate and Reconstitution

Proper handling and administration are essential for safety and efficacy.

• Maximum Infusion Rate: Due to the presence of calcium ions in the formulation, rapid intravenous injection can be dangerous. The infusion rate should not exceed 160 mg of levofolinate per minute to avoid potential cardiac effects of a calcium bolus.[14]
• Reconstitution and Dilution: The lyophilized powder should be reconstituted with sterile water for injection.[36] The resulting solution can be further diluted for infusion using compatible fluids such as 5% Dextrose Injection or 0.9% Sodium Chloride Injection.[14]
• Compatibility: Calcium levofolinate is incompatible with 5-fluorouracil in the same infusion line, as a precipitate may form.[15] They must be administered sequentially. This has prompted the development of a more soluble disodium levofolinate salt, which can be safely mixed with 5-FU in a single infusion bag, simplifying administration and reducing the risk of catheter occlusion.[16]

Monitoring Requirements

Vigilant patient monitoring is a cornerstone of safe calcium levofolinate use, particularly in the context of methotrexate rescue.

• Serum Methotrexate Levels: When used as a rescue agent, serum methotrexate concentrations must be monitored regularly (e.g., daily) to guide the dose and duration of levofolinate therapy. The goal is to continue rescue until the methotrexate level falls below a non-toxic threshold (e.g., <  M).[14]
• Renal Function: Serum creatinine levels must also be monitored daily, as impaired renal function is a primary cause of delayed methotrexate excretion and may necessitate more aggressive levofolinate rescue.[14]

Safety Profile and Risk Management

The safety profile of calcium levofolinate is highly dependent on its clinical context. While it is a remarkably safe drug when used alone, its potential for toxicity increases dramatically when used as a biomodulator of cytotoxic chemotherapy.

Adverse Drug Reactions: Monotherapy vs. Combination Therapy

• Monotherapy: When administered alone, such as for megaloblastic anemia or as a rescue agent after methotrexate has been cleared, adverse effects from calcium levofolinate are rare.[8] The most commonly reported events are occasional high temperature (fever) and hypersensitivity reactions.[8] Allergic reactions can manifest as rash, hives (urticaria), itching, and, in severe cases, anaphylactoid reactions with wheezing and difficulty breathing.[31]
• Combination Therapy with 5-Fluorouracil: The safety profile changes drastically when calcium levofolinate is co-administered with 5-FU. In this setting, levofolinate is not the primary source of toxicity but rather a potent enhancer of 5-FU's adverse effects.[15] The most common, severe, and dose-limiting toxicities are gastrointestinal in nature. These include:
• Diarrhea: Can be severe and lead to dehydration, electrolyte imbalance, and, in some cases, rapid clinical deterioration and death.[24]
• Stomatitis and Mucositis: Painful inflammation and ulceration of the mouth and gastrointestinal tract are very common.[24]
• Myelosuppression: While primarily a toxicity of 5-FU, it can be exacerbated in the combination regimen.[43]

This distinction is critical for clinical management. The adverse events observed during combination therapy are not side effects of levofolinate but are the amplified toxicities of 5-FU. This understanding dictates the correct response to toxicity: it is the dose of the cytotoxic agent (5-FU) that must be reduced or held, not the dose of levofolinate.[24]

Contraindications and High-Risk Patient Populations

There are several absolute contraindications for the use of calcium levofolinate:

• Hypersensitivity: Patients with a known history of severe hypersensitivity to levofolinate, leucovorin, folic acid, or any component of the formulation should not receive the drug.[24]
• Pernicious Anemia: A major contraindication is the treatment of pernicious anemia or other megaloblastic anemias resulting from Vitamin B12 deficiency.[24] Administering folinic acid in this setting can correct the anemia (producing a hematologic remission) but fails to address the underlying B12 deficiency. This can mask the diagnosis and allow the severe and often irreversible neurological manifestations of B12 deficiency to progress.[24]

Certain patient populations are at higher risk for adverse events:

• Elderly and Debilitated Patients: These patients are particularly susceptible to severe gastrointestinal toxicity when receiving the 5-FU/levofolinate combination and require careful monitoring.[24]
• Patients with Renal Impairment: Pre-existing renal insufficiency can delay the excretion of methotrexate, increasing the risk of toxicity and necessitating higher or more prolonged doses of levofolinate rescue.[14]

Clinically Significant Drug-Drug Interactions

Calcium levofolinate participates in several clinically important drug-drug interactions, primarily through pharmacodynamic mechanisms.

Interacting Drug/Class	Mechanism	Clinical Effect	Management Recommendation	Source(s)
Fluoropyrimidines (5-Fluorouracil, Capecitabine)	Pharmacodynamic Synergism	Enhanced therapeutic efficacy and significantly increased toxicity (especially GI).	Monitor closely for toxicity (diarrhea, stomatitis). Reduce the dose of the fluoropyrimidine, not levofolinate, if toxicity occurs.	24
Folic Acid Antagonists (Methotrexate, Trimethoprim, Pyrimethamine)	Pharmacodynamic Antagonism	Reduced or completely neutralized efficacy of the antagonist.	Avoid simultaneous administration unless for intended rescue or overdose treatment. Monitor for treatment failure of the antagonist (e.g., trimethoprim).	15
Anticonvulsants (Phenobarbital, Phenytoin, Primidone)	Decreased plasma concentrations of anticonvulsant.	Increased frequency of seizures in susceptible patients.	Monitor patient for seizure activity. Consider monitoring anticonvulsant plasma levels and adjust dose as necessary during and after levofolinate therapy.	24
Glucarpidase	Increased metabolism of levofolinate.	Decreased levels and potential reduced efficacy of levofolinate rescue.	Monitor closely. Levofolinate is a substrate for glucarpidase.	42

The interaction with anticonvulsants is particularly noteworthy. By potentially increasing the hepatic metabolism of drugs like phenobarbital and phenytoin, levofolinate can lower their plasma concentrations below the therapeutic threshold, leading to a loss of seizure control.[14] This requires vigilant clinical monitoring in epileptic patients receiving cancer therapy.

Global Regulatory Landscape

The regulatory status and branding of calcium levofolinate and its racemic counterpart, leucovorin, vary across major international jurisdictions, reflecting different histories of approval and marketing.

United States (FDA)

In the United States, the purified levo-isomer, levoleucovorin calcium, received its initial FDA approval in March 2008. The approved indications were for rescue after high-dose methotrexate therapy in osteosarcoma and for diminishing the toxicity of folic acid antagonist overdose or impaired methotrexate elimination.[1] In May 2011, the FDA expanded its approval to include use in combination with 5-fluorouracil for the palliative treatment of metastatic colorectal cancer.[28] Approved brand names for levoleucovorin include Fusilev and Khapzory (approved in October 2018).[10]

The racemic form, leucovorin calcium, has a much longer history, having been licensed in the US since 1952.[1] Its brand names include Wellcovorin, which, after being withdrawn, was recently re-approved by the FDA.[31] The FDA is also actively exploring the repurposing of leucovorin calcium for the treatment of cerebral folate deficiency, signaling an expansion of its use into neurological disorders.[6]

Europe (EMA)

In Europe, calcium folinate (referring to the racemic mixture) is widely authorized. In 2003, the European Medicines Agency (EMA) conducted a referral procedure to harmonize the Summary of Product Characteristics (SPCs) across all member states.[47] This was done to resolve discrepancies in nationally approved indications, posology, and contraindications. The harmonized indication is primarily to diminish the toxicity and counteract the action of folic acid antagonists such as methotrexate in cytotoxic therapy and overdose.[48] Approved brand names in the EU include Lederfoline, as well as country-specific names like Calciumfolinat, Lederfolin, Ledervorin Calcium, and Leucovorin.[47] Levoleucovorin is also available and approved in Europe.[49]

Australia (TGA)

In Australia, calcium folinate is regulated by the Therapeutic Goods Administration (TGA) and is listed on the Australian Register of Therapeutic Goods (ARTG).[50] Its approved indications include rescue therapy following high-dose methotrexate and the treatment of certain megaloblastic anemias.[51] An interesting regulatory nuance was noted in 2003, where the use of folinic acid in combination with 5-FU for colorectal cancer, despite being a well-established standard of care, was not an officially TGA-approved indication at the time.[55] This highlights potential gaps between clinical practice guidelines and formal regulatory approvals. Common brand names in Australia include DBL Leucovorin Calcium and Calcium Folinate Ebewe.[51]

Prominent Brand Names and Generic Availability

Globally, calcium levofolinate and leucovorin are marketed under a multitude of brand names. In addition to those mentioned above, foreign brand names for leucovorin/folinate include Adinepar, Calcifolin, Calfolex, Calinat, Cehafolin, Citofolin, Cromatonbic Folinico, Dalisol, Ecofol, Folidan, Folinac, and Lederfolat, among many others.[58] Both levofolinate and racemic leucovorin are widely available as generic medications, increasing access to these essential therapies worldwide.

Synthesis and Expert Analysis

Calcium levofolinate is a refined, potent, and indispensable medication in contemporary medicine. Its value is derived not from intrinsic cytotoxic or curative properties but from its sophisticated ability to modulate the cellular environment, either protecting healthy tissues from harm or amplifying the therapeutic effect of cytotoxic agents. A comprehensive analysis reveals several key conclusions and clinical recommendations for its optimal use.

Integrated Risk-Benefit Assessment in Core Indications

The risk-benefit profile of calcium levofolinate is highly favorable but must be assessed within the context of its specific application.

• In High-Dose Methotrexate Rescue: The benefit is profound and unequivocal. Calcium levofolinate enables the use of potentially curative doses of methotrexate in diseases like osteosarcoma by mitigating life-threatening toxicities. The risks associated with levofolinate itself are minimal, making its use in this setting an absolute necessity with a massively positive risk-benefit ratio.
• In Combination with 5-Fluorouracil: The risk-benefit calculation is more nuanced. The addition of levofolinate provides a clear and significant survival benefit in metastatic colorectal cancer by potentiating 5-FU's efficacy. However, this benefit comes at the direct cost of substantially increased gastrointestinal toxicity, which can be severe and requires vigilant management. The profile remains favorable, but it demands a higher level of clinical surveillance and patient education to manage the associated risks effectively.

Clinical Pearls and Recommendations for Optimal Use

Based on the synthesized evidence, several key principles should guide the clinical use of calcium levofolinate:

1. Strictly Prohibit Intrathecal Administration: The most critical safety warning is the absolute contraindication of intrathecal use, which can be fatal. This must be reinforced through pharmacy protocols, labeling, and clinical education.
2. Timing is Paramount: The clinical outcome is dictated by administration timing. Clinicians must rigorously adhere to delayed administration (rescue) for methotrexate and concurrent administration (potentiation) for 5-FU. Protocols should be clear to prevent catastrophic medication errors.
3. Manage the Partner Drug's Toxicity: In combination therapy, adverse events should be attributed to the cytotoxic agent (e.g., 5-FU). Toxicity management should focus on reducing the dose of 5-FU, not levofolinate.
4. Prefer Levofolinate in Renal Impairment: Given the renal clearance of the inactive d-isomer in racemic leucovorin, the use of pure calcium levofolinate is pharmacologically more precise and may offer a safety advantage by reducing the excretory burden in patients with compromised renal function.
5. Rule Out Pernicious Anemia: Before treating any megaloblastic anemia with levofolinate, a baseline Vitamin B12 level should be assessed to prevent the masking of pernicious anemia and the progression of irreversible neurological damage.

Future Research Directions and Unmet Needs

Despite its long history of use, several areas warrant further investigation:

• Clinical Impact of the D-Isomer: Rigorous clinical trials directly comparing the safety and efficacy of pure levofolinate versus racemic leucovorin are still needed, particularly in vulnerable populations such as the elderly and those with renal or hepatic impairment, to quantify the clinical impact of the "inactive isomer burden."
• Neurological Applications: The emerging role of levofolinate in cerebral folate deficiency is promising. Further robust clinical trials are required to establish definitive efficacy, optimize dosing regimens, and explore its potential in other related neurological and developmental disorders.
• Novel Formulations: The development of more soluble salt forms (e.g., disodium levofolinate) that allow for co-infusion with other agents like 5-FU represents a significant advance in convenience and safety. Research into other novel formulations that could improve stability, simplify administration, or enhance CNS penetration is warranted.
• Biomarkers for Toxicity: Identifying biomarkers that could predict which patients are most likely to experience severe toxicity from the 5-FU/levofolinate combination would allow for more personalized dosing strategies and improved patient safety.

In conclusion, calcium levofolinate is a testament to the power of adjuvant therapy in medicine. Its sophisticated, dual-action pharmacology has transformed cancer treatment, enabling both higher-intensity curative therapies and more effective palliative regimens. Its continued study and careful application will ensure it remains a vital tool in the clinical armamentarium for years to come.

Works cited

1. Medical Review(s) - accessdata.fda.gov, accessed October 9, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/020140s000medR.pdf
2. Levoleucovorin calcium | DrugBank Online, accessed October 9, 2025, https://go.drugbank.com/salts/DBSALT001886
3. Levoleucovorin Calcium | C20H21CaN7O7 | CID 135500522 - PubChem, accessed October 9, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Levoleucovorin-Calcium
4. Calcium Levofolinate - GMT Fine Chemicals SA - Reduced Folates, accessed October 9, 2025, https://gmt.swiss/product/calcium-levofolinate/
5. Leucovorin: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed October 9, 2025, https://go.drugbank.com/drugs/DB00650
6. Folinic acid - Wikipedia, accessed October 9, 2025, https://en.wikipedia.org/wiki/Folinic_acid
7. DRUG NAME: Leucovorin - BC Cancer, accessed October 9, 2025, http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Leucovorin_monograph.pdf
8. Folinic acid (calcium folinate or leucovorin) | Macmillan Cancer ..., accessed October 9, 2025, https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/folinic-acid-leucovorin-calcium-folinate
9. Calcium Levofolinate | CAS:80433-71-2 | High Purity | Manufacturer BioCrick, accessed October 9, 2025, https://www.biocrick.com/Calcium-Levofolinate-BCC4643.html
10. Levoleucovorin: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed October 9, 2025, https://go.drugbank.com/drugs/DB11596
11. calcium levofolinate | C20H21CaN7O7 - ChemSpider, accessed October 9, 2025, https://www.chemspider.com/Chemical-Structure.8068253.html
12. Calcium Folinate | DHFR inhibitor | Mechanism | Concentration - Selleck Chemicals, accessed October 9, 2025, https://www.selleckchem.com/products/calcium-levofolinate-calcium-folinate.html
13. FULL PRESCRIBING INFORMATION - accessdata.fda.gov, accessed October 9, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020140s024lbl.pdf
14. LEUCOVORIN CALCIUM INJECTION - Pfizer, accessed October 9, 2025, https://labeling.pfizer.com/ShowLabeling.aspx?id=12786
15. LEUCOVORIN CALCIUM INJECTION Label - accessdata.fda.gov, accessed October 9, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/040347s010lbl.pdf
16. Major innovations and clinical applications of disodium-levofolinate ..., accessed October 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6552345/
17. Calcium Levofolinate - APExBIO, accessed October 9, 2025, https://www.apexbt.com/calcium-levofolinate.html
18. Leucovorin Calcium - NCI, accessed October 9, 2025, https://www.cancer.gov/about-cancer/treatment/drugs/leucovorincalcium
19. Folate and folic acid for use in listed medicines | Therapeutic Goods Administration (TGA), accessed October 9, 2025, https://www.tga.gov.au/products/medicines/non-prescription-medicines/listed-medicines/folate-and-folic-acid-use-listed-medicines
20. What is the mechanism of Levoleucovorin? - Patsnap Synapse, accessed October 9, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-levoleucovorin
21. Pharmacology Review(s) - accessdata.fda.gov, accessed October 9, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/020140s000PharmR.pdf
22. Folinic Acid - StatPearls - NCBI Bookshelf, accessed October 9, 2025, https://www.ncbi.nlm.nih.gov/books/NBK545232/
23. leucovorin - Cancer Care Ontario, accessed October 9, 2025, https://www.cancercareontario.ca/en/node/43961
24. Calcium Folinate Injection, accessed October 9, 2025, https://labeling.pfizer.com/ShowLabeling.aspx?id=12130
25. Calcium Folinate 15mg Tablets - Summary of Product Characteristics (SmPC) - (emc) | 6343, accessed October 9, 2025, https://www.medicines.org.uk/emc/product/6343/smpc
26. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Levofolinic acid 50 mg/ml solution for injection/infusion 2. - Medac eu, accessed October 9, 2025, https://www.medac.eu/fileadmin/user_upload/medac-eu/SPCs/common_SPCs/Levofolinic-spc-common.pdf
27. Levoleucovorin calcium pentahydrate | DrugBank Online, accessed October 9, 2025, https://go.drugbank.com/salts/DBSALT001887
28. Levoleucovorin (Fusilev® and Khapzory ) IV - Medical Coverage Guideline - Florida Blue, accessed October 9, 2025, http://mcgs.bcbsfl.com/MCG?mcgId=09-J2000-31&pv=false
29. Spectrum Pharmaceuticals Receives FDA Approval of KHAPZORY™ (levoleucovorin) for injection - Florida Society of Clinical Oncology, accessed October 9, 2025, https://flasco.org/spectrum-pharmaceuticals-receives-fda-approval-of-khapzory-levoleucovorin-for-injection/
30. FDA Approves Levoleucovorin for Injection for mCRC, Osteosarcoma - ACCC Cancer, accessed October 9, 2025, https://www.accc-cancer.org/detail-pages/blurb-discussion-detail/fda-approves-levoleucovorin-for-injection-for-mcrc-osteosarcoma
31. Leucovorin (Wellcovorin): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing, accessed October 9, 2025, https://www.webmd.com/drugs/2/drug-1498/leucovorin-calcium-oral/details
32. Approval of Previously Withdrawn New Drug ... - Federal Register, accessed October 9, 2025, https://www.federalregister.gov/documents/2025/09/24/2025-18510/approval-of-previously-withdrawn-new-drug-application-for-wellcovorin-leucovorin-calcium-tablets
33. FDA Approves Leucovorin Calcium Tablets to Treat Cerebral Folate Deficiency, accessed October 9, 2025, https://www.consultant360.com/fda-alerts/fda-approves-leucovorin-calcium-tablets-treat-cerebral-folate-deficiency
34. FDA Initiates Approval of Leucovorin for Patients With Cerebral Folate Deficiency, accessed October 9, 2025, https://www.pharmacytimes.com/view/fda-initiates-approval-of-leucovorin-calcium-tablets-for-patients-with-cerebral-folate-deficiency
35. FDA Takes Action to Make a Treatment Available for Autism Symptoms, accessed October 9, 2025, https://www.fda.gov/news-events/press-announcements/fda-takes-action-make-treatment-available-autism-symptoms
36. Folinic acid (calcium folinate, calcium leucovorin) Intravenous for Adults | Medinfo Galway, accessed October 9, 2025, https://medinfogalway.ie/ivguides/folinic-acid-calcium-folinate-calcium-leucovorin-intravenous-adults
37. Leucovorin - StatPearls - NCBI Bookshelf, accessed October 9, 2025, https://www.ncbi.nlm.nih.gov/books/NBK553114/
38. Leucovorin (oral route, intravenous route, injection route) - Side effects & dosage, accessed October 9, 2025, https://www.mayoclinic.org/drugs-supplements/leucovorin-oral-route-intravenous-route-injection-route/description/drg-20064503
39. Levoleucovorin calcium (Levoleucovorin calcium Injection): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed October 9, 2025, https://www.rxlist.com/levoleucovorin-calcium-drug.htm
40. PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION ..., accessed October 9, 2025, https://pdf.hres.ca/dpd_pm/00071726.PDF
41. Leucovorin: MedlinePlus Drug Information, accessed October 9, 2025, https://medlineplus.gov/druginfo/meds/a682336.html
42. leucovorin dosing, indications, interactions, adverse effects, and more, accessed October 9, 2025, https://reference.medscape.com/drug/leucovorin-343736
43. Side effects of Calcium levofolinate - ChemicalBook, accessed October 9, 2025, https://www.chemicalbook.com/article/side-effects-of-levofolinate-calcium.htm
44. Product Monograph Including Patient Medication Information PrLEUCOVORIN CALCIUM INJECTION USP Leucovorin Calcium Injection Solu, accessed October 9, 2025, https://pdf.hres.ca/dpd_pm/00081270.PDF
45. Search Orphan Drug Designations and Approvals - FDA, accessed October 9, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=48490
46. FDA Approves FUSILEV® for Use in Patients with Colorectal Cancer | Fierce Biotech, accessed October 9, 2025, https://www.fiercebiotech.com/biotech/fda-approves-fusilev%C2%AE-for-use-patients-colorectal-cancer
47. Lederfoline - referral | European Medicines Agency (EMA), accessed October 9, 2025, https://www.ema.europa.eu/en/medicines/human/referrals/lederfoline
48. Union Register of medicinal products - Public health - European ..., accessed October 9, 2025, https://ec.europa.eu/health/documents/community-register/html/ho1645.htm
49. Levoleucovorin | Marketing Authorisations | MA | Europe - PharmaCompass.com, accessed October 9, 2025, https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/levoleucovorin
50. (Approval lapsed) Leucovorin calcium injection 100mg/10mL lyophilized powder for solution, accessed October 9, 2025, https://www.tga.gov.au/resources/section-19a-approvals/approval-lapsed-leucovorin-calcium-injection-100mg10ml-lyophilized-powder-solution
51. DBL Leucovorin Calcium injection and tablets - NPS MedicineWise, accessed October 9, 2025, https://www.nps.org.au/medicine-finder/leucovorin-calcium-injection-usp
52. Leucovorin Calcium (Pfizer) - Healthdirect, accessed October 9, 2025, https://www.healthdirect.gov.au/medicines/brand/amt,1357851000168105/leucovorin-calcium-pfizer
53. DBL LEUCOVORIN CALCIUM folinic acid 15 mg (as calcium folinate hydrate) tablet bottle (16364) | Therapeutic Goods Administration (TGA), accessed October 9, 2025, https://www.tga.gov.au/resources/artg/16364
54. Pfizer (Australia) LEUCOVORIN CALCIUM folinic acid (as calcium folinate) 100mg/10mL injection USP ampoule (61887) | Therapeutic Goods Administration (TGA), accessed October 9, 2025, https://www.tga.gov.au/resources/artg/61887
55. Folinic acid, the PBAC and the TGA - approval confusion - Australian Prescriber, accessed October 9, 2025, https://australianprescriber.tg.org.au/articles/folinic-acid-the-pbac-and-the-tga-approval-confusion.html
56. Calcium Folinate (Ebewe) | healthdirect, accessed October 9, 2025, https://www.healthdirect.gov.au/medicines/brand/amt,929362011000036108/calcium-folinate-ebewe
57. DBL Leucovorin Calcium - NPS MedicineWise, accessed October 9, 2025, https://www.nps.org.au/medicine-finder/dbl-leucovorin-calcium
58. Definition of leucovorin calcium - NCI Drug Dictionary, accessed October 9, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/leucovorin-calcium
59. Leucovorin calcium - KEGG DRUG - (www.genome.jp)., accessed October 9, 2025, https://www.genome.jp/dbget-bin/www_bget?D01211